HALP Score Examined as a Kidney Risk Marker in NHANES Adults
A large NHANES-based analysis set out to clarify whether the hemoglobin albumin lymphocyte and platelet score, or HALP, tracks with chronic kidney disease in adults. The biomarker has already been used in other chronic disease settings because it folds together signals from nutrition, systemic inflammation, and hematologic reserve into a single composite measure. In kidney medicine, that kind of composite marker is attractive for a simple reason: CKD rarely develops in a biologic vacuum. Declining kidney function often moves alongside anemia, protein-energy wasting, inflammatory activation, and immune dysfunction, all of which can depress the individual components that make up HALP.
The study drew on 25,181 adults from NHANES cycles spanning 2009 to 2018. Researchers used weighted multivariable logistic regression and generalized additive models to test independent associations between HALP and three outcomes: CKD, albuminuria, and low estimated glomerular filtration rate. CKD was defined by either albuminuria, using a urinary albumin-to-creatinine ratio of at least 30 mg/g, or low eGFR. This dual definition matters clinically because kidney injury can surface first as glomerular leak before filtration falls, or as filtration loss before overt albumin spill becomes obvious. A biomarker that aligns with both pathways would be more useful than one tied to only a single laboratory abnormality.
Why a Composite Nutritional-Inflammatory Marker Could Matter in Kidney Disease
HALP is not a kidney-specific marker, and that is part of its appeal. Hemoglobin reflects oxygen-carrying capacity and often falls in chronic kidney disease because reduced erythropoietin production, iron restriction, inflammation, and chronic illness suppress erythropoiesis. Albumin serves as a rough clinical readout of nutritional status and systemic inflammatory burden, although it is also influenced by hydration, hepatic synthesis, and urinary loss. Lymphocyte and platelet counts add another layer, capturing immune competence and inflammatory tone. In a disease such as CKD, where chronic inflammation and metabolic stress often coexist, a low HALP score could plausibly mirror a physiologic state that is already hostile to renal preservation.
That biologic logic gives the analysis real bedside relevance. Nephrology already relies on simple blood and urine tests to stratify risk, but those tests are usually interpreted separately. A composite score can sometimes reveal a broader phenotype than any one lab value alone. If HALP correlates with albuminuria or impaired eGFR after adjustment for other factors, it could become a practical screening adjunct in population health settings, outpatient follow-up, or risk enrichment strategies for further renal evaluation. It would not replace urine albumin testing or creatinine-based staging, but it could help identify patients whose inflammatory and nutritional profile is already shifting in an unfavorable direction.
The study design also shows why the question was asked in a nationally representative sample rather than a narrow nephrology cohort. NHANES includes adults from the general population, which allows investigators to examine whether HALP has signal beyond patients already known to have kidney disease. That matters because a biomarker that only works in advanced disease is less useful for prevention. A marker that begins to separate risk earlier, before fixed renal damage accumulates, has more potential clinical value.
Cross-Sectional Data Can Signal Association, Not Causation
The statistical approach used here was built to ask whether HALP and CKD move together after accounting for other variables, not whether one causes the other. That distinction is central. Cross-sectional data can identify a relationship, but they cannot determine whether low HALP contributes to kidney injury, whether CKD lowers HALP through inflammation and malnutrition, or whether both are being driven by a third process such as diabetes, vascular disease, or socioeconomic disadvantage. In kidney medicine, reverse causality is always plausible because renal dysfunction itself can reshape nutrition, immunity, and blood indices.
The inclusion of generalized additive models suggests the analysis also looked for non-linear patterns, which is clinically sensible. Biomarker associations in CKD often do not follow a straight line. A modest drop in hemoglobin or albumin may carry different meaning at different baseline levels, and the combined score could behave similarly. A non-linear relationship would fit the biology of chronic kidney injury, where risk often accelerates after compensatory reserve has been exhausted.
What the HALP Framework Adds to Renal Risk Thinking
From a practical standpoint, HALP offers a compact way to summarize several domains that nephrologists already care about: anemia, nutrition, inflammation, and immune status. Those are not abstract concepts in CKD. They influence fatigue, frailty, susceptibility to infection, cardiovascular risk, and the tempo of progression. A biomarker that integrates these features could help clinicians think more holistically about a patient whose creatinine may not tell the full story.
The challenge is that any composite score must earn its place against familiar tools. Urine albumin-to-creatinine ratio, serum creatinine, and eGFR remain the backbone of CKD detection and staging. HALP would need to show that it adds information beyond standard labs and comorbidity assessment before it could be used routinely. Without that proof, it remains an interesting epidemiologic signal rather than a bedside decision rule.
The broader implication is straightforward. Chronic kidney disease is not only a filtration disorder; it is also a disorder of systemic stress, inflammation, and loss of physiologic reserve. HALP was designed to capture exactly those elements, which is why its association with CKD deserves scrutiny. The remaining question for clinicians is not whether the score is biologically plausible, but whether it changes prediction, detection, or management once conventional renal markers are already in hand.